Table 2.
Variables associated with 14-day overall mortality.
| Variable | Yes, No. (%) |
No, No. (%) |
P-value |
|---|---|---|---|
| No. of patients | 56 (16.5) | 283 (83.5) | |
| Age in years, median (range) | 68 (38–98) | 65 (22–93) | 0.45 |
| Gender, male | 33 (58.9) | 181 (63.9) | 0.55 |
| Underlying disease/condition | |||
| Cardiovascular disease | 10 (17.9) | 39 (13.8) | 0.41 |
| Diabetes mellitus | 30 (53.6) | 107 (37.8) | 0.04 |
| Uremia requiring dialysis | 10 (17.9) | 56 (19.8) | 0.85 |
| Decompensated liver cirrhosis | 10 (17.9) | 37 (13.1) | 0.40 |
| Malignancies | 9 (16.1) | 55 (19.4) | 0.71 |
| Prosthetic device implantation | 6 (10.7) | 35 (12.4) | 0.83 |
| Severity-of-illness markera | |||
| Nosocomial acquisition | 46 (82.1) | 199 (70.3) | 0.07 |
| Intensive care unit admission | 16 (28.6) | 59 (20.8) | 0.22 |
| APACHE II score, median (range) | 18 (1–31) | 17 (2–38) | 0.19 |
| APACHE II score > 15 | 13 (23.2) | 31 (10.9) | 0.03 |
| Source of infectionb | |||
| Catheter-related infection | 1 (1.8) | 39 (13.8) | <0.01 |
| Endovascular infection | 0 | 9 (3.2) | 0.37 |
| Soft-tissue infection | 10 (17.9) | 79 (27.9) | 0.42 |
| Osteomyelitis | 12 (21.4) | 55 (19.4) | 0.72 |
| Urinary tract infection | 0 | 4 (1.4) | 1.00 |
| Pneumonia | 20 (35.7) | 31 (10.9) | <0.01 |
| Primary bacteremia | 10 (17.9) | 64 (21.8) | 0.48 |
| Timing of initiating glycopeptide therapy | |||
| Before preliminary BC report indicated SLO growth and within 24 h after BC indicated SLO growth | 36 (64.3) | 155 (54.8) | 0.24 |
BC: blood culture; MRSA: methicillin-resistant S. aureus; No.: number; SLO: Staphylococcus-like organism.
aAt time of blood culture sampling.
bSome patients had more than one infected site.